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Introduction
This is an executive summary of all consented recommendations
of the European Psoriasis Guidelines – Update 2015. The long ver-
sion of this guideline is available online as supplementary file. A
detailed description of the used methodology can be found in the
methods report (DOI: 10.1111/jdv.13353).
In brief, available evidence of the efficacy and safety of the sys-
temic treatments for psoriasis including an assessment of the quality
of evidence was summarized using GRADE (Grading of Recommen-
dations Assessment, Development and Evaluation).1 The end of the
literature search was October 12th, 2014. Some parts of the guideli-
nes are based on a complete literature review (marked as evidence
based), other parts are based on expert consensus only (marked as
expert opinion). All recommendations (highlighted in grey) were
formulated and consented by an expert panel, officially nominated
by the European Dermatology Forum (EDF), the European Associa-
tion for Dermatology and Venereology (EADV) or the International
Psoriasis Council (IPC).
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For the chapters of ‘Special considerations and special patient
populations’, the literature was not systematically assessed and the
recommendations are based on expert opinion only.
All recommendations were consented using formal consensus
methodology (Delphi process or consensus conference with nominal
group technique).2,3 Based on the GRADE approach, the strength of
recommendation is expressed by the wording and symbols shown in
Table 1.
For each recommendation, the strength of consensus in terms of
percentage of agreement was measured and documented. Three
levels of consensus were defined and distinguished: ‘strong consen-
sus’ (agreement of >90% of the members of the expert group), ‘con-
sensus’ (75–89% agreement) and ‘weak consensus’ (50–74%
agreement).
The guidelines have a validity until 31.12.2019.
Table 1 Strength of recommendations: wording, symbols and implications4,5
Strength Wording Symbol
Strong recommendation for the use of an intervention ‘We recommend . . .’ ↑↑
Weak recommendation for the use of an intervention ‘We suggest . . .’ ↑
No recommendation with respect to an intervention ‘We cannot make a recommendation with respect to . . .’ o
Weak recommendation against the use of an intervention ‘We suggest not . . .’ ↓
Strong recommendation against the use of an intervention ‘We recommend not . . .’ ↓↓
Conventional systemic therapy
Acitretin
Instructions for use
Pre-treatment
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• History and clinical examination should focus on musculoskeletal problems. If patient reports complaints, further imaging
investigation may be performed
• Exclude pregnancy/breastfeeding: patient must be informed explicitly and extensively about the teratogenic risk of the medi-
cation, the necessity of effective long-term contraception (at least two years after cessation of treatment) and the possible
consequences of a pregnancy while taking retinoids; written documentation of this informational interview
• Note that during and up to one year after treatment, blood donation is not permitted
• Laboratory controls (see Table 2)
During treatment
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• Take capsules with a fatty meal or with whole milk
• Avoidance of pregnancy is mandatory. Start treatment on second or third day of the menstrual cycle, after satisfactory con-
traception for at least one month prior to treatment. Double contraception is recommended (e.g. condom + pill; IUD/
Nuva Ring + pill; cave: no low-dosed progesterone preparations/mini-pills) during and up to two years after the end of
therapy; effectiveness of oral contraceptives is reduced by acitretin
• Avoidance of alcohol
• Ask patient about spine and joint complaints at follow-up visits. If patient reports complaints, further imaging investigation
may be performed
• Laboratory controls (see Table 2)
Post-treatment
• Reliable contraception in women of child-bearing age for up to two years after therapy, double contraception, as described
above, is recommended
• Patients may not donate blood for up to one year after the discontinuation of therapy
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Table 2 Recommended lab controls – acitretin
Parameter Period in weeks
Pre-treatment 1 2 4 8 12 16
Blood count* x x x
Liver enzymes** x x x
Serum creatinine x
Pregnancy test (urine) x Monthly up to 2 years after therapy (see national regulations)
Fasting blood glucose x
Triglycerides, cholesterol, HDL x x x
Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further speciﬁc
testing may be required according to clinical signs, risk and exposure.
*Hb, Hct, leucocytes, platelets.
**AST, ALT, AP, cGT.
Recommendation Strength of consensus Comment
Based on the available evidence we cannot make a recommendation for
or against the use of acitretin as a monotherapy.
o Consensus Evidence and consensus based
Based on clinical experience and depending on the most important
outcome for the individual patient, we suggest a low dose (20–30 mg
daily) with respect to tolerability and a high dose (>30 mg daily) with
respect to efﬁcacy.
↑ Consensus Expert opinion
Recommendation Strength of consensus Comments
Adalimumab o Consensus No evidence available
Ciclosporin ↓ Strong consensus Expert opinion: competition cytochrome P450 inactivation
Etanercept ↑ Consensus Expert opinion: good safety proﬁle assumed, possibly increased efﬁcacy
Fumaric acid esters o Consensus No evidence available
Inﬂiximab o Consensus No evidence available
Methotrexate ↓ Strong consensus Expert opinion: increased risk of hepatotoxicity possible
Ustekinumab o Consensus No evidence available
Therapeutic recommendations
Therapeutic combinations
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Ciclosporin
Instructions for use
Pre-treatment
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/ Skindex-29 or -17)
• History and clinical examination should focus on previous and concomitant diseases (e.g. arterial hypertension; severe
infections; malignancies, including cutaneous malignancies; renal and liver diseases) and concomitant medication (see Drug
interactions, long version)
• Measurement of blood pressure on two separate occasions
• Laboratory controls (see Table 3)
• Reliable contraception (cave: reduced efficacy of progesterone-containing contraceptives)
• Regular gynaecologic screening according to national guidelines
• Consultation on vaccination; susceptibility to infections (take infections seriously, seek medical attention promptly); drug
interactions (inform other treating physicians about therapy); avoidance of excessive sun exposure; use of sunscreens
During treatment
In uncomplicated long-term therapy with low-dose ciclosporin (CSA; 2.5–3 mg/kg daily), follow-up intervals may be extended to two
months or more. Shorter intervals may be needed in patients with risk factors, dose increases, or those who must take concomitant
medications that are likely to contribute to ADR. In selected patients with intermittent and short-term treatment, less strict monitor-
ing (regular checking of blood pressure and creatinine level) may be sufficient.
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• Clinical examination should focus on the status of skin and mucous membranes (hypertrichosis, gingival changes), signs of
infections, gastrointestinal or neurological symptoms (tremor, dysaesthesia) and musculoskeletal/joint pain
• Repeat recommendation for sun avoidance and sun protection
• Check of concomitant medication
• Measurement of blood pressure
• Laboratory controls (see Table 3)
• Reliable contraception
• Regular gynaecologic screening according to national guidelines
• If creatinine is significantly elevated and/or patient on therapy for >1 year, perform creatinine clearance (or creatinine-
EDTA clearance where available).
• Determination of the CSA level is recommended in individual cases.
Post-treatment
• After discontinuation of CSA, patients should be followed up for skin cancer, especially in case of extensive prior therapeutic
or natural UV exposure.
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Recommendation Strength of consensus Comment
If a short course for induction treatment is intended we recommend
CSA.
↑↑ Strong consensus Evidence and consensus based
For long-term treatment we suggest CSA only in selected patients. ↑ Strong consensus Expert opinion
In case of continuous long-term treatment, we suggest CSA for a
maximum of up to two years.
↑ Consensus Expert opinion
In case a longer treatment is needed, we suggest the consultation
with a nephrologist.
↑ Consensus Expert opinion
Based on weighting of risk and beneﬁt we suggest using CSA with a
starting dose of 2.5 mg/kg bodyweight QD for up to four weeks, with
a dosage increase up to 5 mg/kg bodyweight once daily thereafter.
↑ Weak consensus Evidence and consensus based
Table 3 Recommended lab controls – ciclosporin
Diagnostics Period in weeks
Pre-treatment 2 4 8 12 16
Full blood count* x x x x x x
Liver values** x x x x x x
Electrolytes*** x x x x x x
Serum creatinine x x x x x x
Urine status x x x
Uric acid x x x x x
Pregnancy test (urine) x
Cholesterol, triglycerides x**** x x
Magnesium***** x x x
HBV/HCV x
HIV x
Not all tests may be necessary for all patients. Patient history, risk exposure and patient
characteristics have to be taken into account. Further speciﬁc testing may be required according to
clinical signs, risk and exposure.
*Erythrocytes, leucocytes, platelets.
**Transaminases, AP, cGT, bilirubin.
***Sodium, potassium.
****Recommended two weeks before and on the day of treatment initiation (fasting).
*****Only with indication (muscle cramps).
Therapeutic recommendations
Recommendation Strength of consensus Comments
Acitretin ↓ Strong consensus Expert opinion: competition cytochrome P450 inactivation
Adalimumab ↓ Consensus Expert opinion: increased risk of immunosuppression
Etanercept ↓ Consensus Expert opinion: increased risk of immunosuppression
Fumaric acid esters o Consensus No evidence available
Inﬂiximab ↓ Consensus Expert opinion: increased risk of immunosuppression
Methotrexate ↓ Weak consensus Expert opinion: increased risk of immunosuppression
Ustekinumab ↓ Consensus Expert opinion: increased immunosuppression, anecdotal evidence of increased toxicity
Therapeutic combinations
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Fumaric acid esters
Instructions for use
Pre-treatment
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• History and clinical examination
• Laboratory controls (see Table 4)
During treatment
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• Clinical examination
• Laboratory controls (see Table 4)
Post-treatment
• None.
Therapeutic recommendations
Table 4 Recommended lab controls – fumaric acid esters
Parameter Period in weeks
Pre-treatment Month 1 Every 4 weeks until
month 4
Thereafter
Liver enzymes x x x every 8 weeks
Serum creatinine x x x every 8 weeks
Urine status x x x every 8 weeks
Pregnancy test x
Blood count* x x x every 4 weeks**
Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have
to be taken into account. Further speciﬁc testing may be required according to clinical signs, risk and
exposure.
*If leukocytes are <3000/ll, fumarate therapy needs to be stopped. If lymphocytes are <700/ll, patients should
be kept on half of the last dose for 2–4 weeks and stopped if lymphocytes remain below 700/ll; if lymphocytes
are <500/ll, treatment must be terminated.
**Frequency of lab control of blood count was a matter of debate, including repeated Delphi voting. No strong
consensus was achieved, the recommendation passed with ‘weak consensus’ (63%).
Recommendation Strength of consensus Comment
We recommend fumaric acid esters for the induction treatment. ↑↑ Consensus Evidence and consensus based
We recommend fumaric acid esters for the long-term treatment. ↑↑ Consensus Expert opinion
We recommend fumaric acid esters with a slow increase dosing
regimen.
↑↑ Consensus Expert opinion
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Therapeutic combinations
Recommendation Strength of consensus Comments
Acitretin o Consensus No evidence available
Adalimumab o Strong consensus No evidence available
Ciclosporin o Consensus No evidence available
Etanercept o Strong consensus No evidence available
Inﬂiximab ↓ Consensus Expert opinion: increased risk of immunosuppression,
lymphocytopenia
Methotrexate ↓ Consensus Expert opinion: increased risk of immunosuppression
Ustekinumab o Consensus No evidence available
Methotrexate
Instructions for use
Pre-treatment
• History and clinical examination
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• Laboratory parameters (see Table 5)
• Chest X-ray
• Contraception in women of child-bearing age (starting after menstruation), and also in men
• If abnormalities in liver screening are found, refer patient to specialist for further evaluation
During treatment
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• Check concomitant medication
• Clinical examination
• Laboratory controls (see Table 5)
• Contraception in women of child-bearing age, and also in men
• 5 mg folic acid once weekly, 24 h after MTX
Post-treatment
• Women must not become pregnant and men must not father a child for at least three months thereafter
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Table 5 Recommended lab controls –methotrexate
Parameter Period in weeks/months
Pre-treatment After ﬁrst
week
During ﬁrst two months,
1 3 every 2 weeks
Thereafter,
every 2–3 months
Blood count* x x x x
Liver enzymes x x x
Serum creatinine x x x
Urine status x x x
Pregnancy test (urine) x
HBV/HCV x
HIV x
Serum albumin** x x x
PIIINP where available x Every 3 months***
Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have
to be taken into account. Further speciﬁc testing may be required according to clinical signs, risk and
exposure.
*If blood leucocytes <3.0, neutrophils <1.0, thrombocytes <100, or liver enzymes >2 9 baseline values,
decrease the dose or discontinue the medication.
**In selected cases (e.g. in cases with suspected hypoalbuminaemia or in patients using other drugs with high
binding afﬁnity for serum albumin).
***Liver biopsy when necessary in selected cases; should be considered, for example, in patients with persis-
tently abnormal PIIINP (>4.2 mcg/l in at least three samples over a 12-month period).
Therapeutic recommendations
Therapeutic combinations
Recommendation Strength of consensus Comment
We recommend MTX for the induction and long-term treatment. ↑↑ Strong consensus Evidence and consensus based
Methotrexate can be given by oral or subcutaneous delivery. In general, a
starting dose of 15 mg/week is used but individual dosages can range from
5 to 25 mg/week depending on individual factors.
Statement Strong consensus Expert opinion
Recommendation Strength of consensus Comments
Acitretin ↓ Strong consensus Expert opinion: increased risk of hepatotoxicity possible
Adalimumab ↑ Consensus Expert opinion: combination widely used in rheumatology; combination with low-dose MTX (e.g.
7.5–10 mg/week is likely sufﬁcient to reduce formation of anti-drug antibodies (ADA) and
increase trough levels of adalimumab)
Ciclosporin ↓ Weak consensus Expert opinion: increased risk of immunosuppression
Etanercept ↑ Consensus Evidence (additional beneﬁt of adding MTX to etanercept compared to etanercept monotherapy)
and consensus based
Fumaric acid esters ↓ Consensus Expert opinion: increased risk of immunosuppression
Inﬂiximab ↑ Consensus Expert opinion: combination widely used in rheumatology; combination with low-dose MTX (e.g.
7.5–10 mg/week is likely sufﬁcient to reduce formation of ADA and increase trough levels of
inﬂiximab)
Ustekinumab o Consensus No evidence available
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Biological therapy
Adalimumab
Instructions for use
Pre-treatment
• Physicians are encouraged to enrol their patients in a registry (if available)
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• History and clinical examination should focus on prior exposure to treatments, malignancies, infections, congestive heart
failure (CHF) and neurological disease or symptoms
• Recommended measures include:
- Check for skin cancer
- Check for lymphadenopathy
- Laboratory parameters (see Table 6)
- Exclusion of tuberculosis (see chapter 5.1 in long version)
- Check for evidence of active infection
• Contraception
During treatment
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• Clinical examination should focus on malignancies, risk factors for serious infections, congestive heart failure and neurolog-
ical symptoms
• Recommended measures include:
- Check for skin cancer
- Check for lymphadenopathy
- Laboratory parameters (see Table 6)
• Contraception
Post-treatment
• After discontinuation of adalimumab, patients should be followed up with medical history and physical examination
• Reliable contraception until five months after treatment, if applicable (according to the label)
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Table 6 Recommended lab controls – adalimumab
Parameter Period in weeks
Pre-treatment 4 12 Thereafter,
every 3–6 months
Full blood count x x x x
Liver enzymes x x x x
Serum creatinine x x x x
Urine status x x x x
Pregnancy test
(urine)
x
CRP x
HBV/HCV x
HIV x
Not all tests may be necessary for all patients. Patient history, risk exposure and patient
characteristics have to be taken into account. Further speciﬁc testing may be required
according to clinical signs, risk and exposure.
Therapeutic recommendations
Therapeutic combinations
Recommendation Strength of consensus Comment
We recommend adalimumab as second-line medication* for the induction and
long-term treatment.
↑↑ Strong consensus Evidence and consensus based
We recommend using adalimumab with an initial loading dose of 80 mg for week 1,
followed by 40 mg every other week.
↑ Strong consensus Expert opinion
*If phototherapy and conventional systemic agents were inadequate in response or if they are contraindicated or not tolerated.
Recommendation Strength of consensus Comments
Acitretin o Consensus No evidence available
Ciclosporin ↓ Consensus Expert opinion: increased risk of immunosuppression
Fumaric acid esters o Strong consensus No evidence available
Methotrexate ↑ Consensus Expert opinion: combination widely used in rheumatology; combination
with low-dose MTX (e.g. 7.5–10 mg/week is likely sufﬁcient to reduce
formation of ADA and increase trough levels of adalimumab)
Ustekinumab ↓ Consensus Expert opinion: increased risk of immunosuppression
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Etanercept
Instructions for use
Pre-treatment
• Physicians are encouraged to enrol their patients in a registry (if available)
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• History and clinical examination should focus on prior exposure to treatments, malignancies, infection, congestive heart
failure and neurological symptoms
• Recommended measures include:
- Check for malignancy, mainly skin cancer and pre-malignant lesions
- Check for lymphadenopathy
- Laboratory parameters (see Table 7)
- Exclusion of tuberculosis (see chapter 5.1 in long version)
- Check for evidence of active infection
• Contraception
During treatment
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL such as (DLQI/Skindex-29 or -17)
• Clinical examination should focus on lymphadenopathy, malignancies, especially skin cancer, premalignant lesions, risk fac-
tors for serious infections, congestive heart failure and neurological symptoms
• Recommended measures include:
- Laboratory parameters (see Table 7)
• Contraception
Post-treatment
• After discontinuation of etanercept, patients should be followed up with medical history and physical examination.
• Women of childbearing potential should be advised to use appropriate contraception to avoid becoming pregnant for three
weeks after discontinuation of therapy.
Table 7 Recommended lab controls – etanercept
Parameter Period in weeks
Pre-treatment 4 12 Thereafter,
every 3–6 months
Full blood count x x x x
Liver enzymes x x x x
Serum creatinine x x x x
Urine status x
Pregnancy test (urine) x
CRP x
HBV/HCV x
HIV x
Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have
to be taken into account. Further speciﬁc testing may be required according to clinical signs, risk and
exposure.
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Recommendation Strength of consensus Comment
We recommend etanercept as second-line* medication for the induction
and long-term treatment.
↑↑ Strong consensus Evidence and consensus based
In general, a starting dose of 50 mg once or twice weekly is used
depending on individual factors.
Statement Strong consensus Expert opinion
For maintenance therapy 50 mg once weekly is a commonly used dose. Statement Strong consensus Expert opinion
*If phototherapy and conventional systemic agents were inadequate in response or if they are contraindicated or not tolerated.
Recommendation Strength of consensus Comments
Acitretin ↑ Consensus Expert opinion: good safety proﬁle assumed, possibly increased efﬁcacy
Ciclosporin ↓ Consensus Expert opinion: increased risk of immunosuppression
Fumaric acid esters o Strong consensus No evidence available
Methotrexate ↑ Consensus Evidence (additional beneﬁt of adding MTX to etanercept compared to etanercept
monotherapy) and consensus based
Ustekinumab ↓ Consensus Expert opinion: increased risk of immunosuppression
Therapeutic recommendations
Therapeutic combinations
Inﬂiximab
Instructions for use
Pre-treatment
• Physicians are encouraged to enrol their patients in a registry (if available)
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• History focusing on prior exposure to treatments. History and clinical examination should focus on malignancies, infection,
congestive heart failure and neurological symptoms
• Recommended measures include:
- Check for skin cancer
- Check for lymphoadenopathy
- Laboratory parameters (see Table 8)
- Exclusion of tuberculosis (see chapter 5.1 in long version)
- Check for evidence of active infection
• Contraception
During treatment
• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/ Skindex-29 or -17)
• Clinical examination should focus on malignancies, risk factors for serious infections, congestive heart failure and neurolog-
ical symptoms
• Recommended measures include:
- Check for skin cancer
- Check for lymphoadenopathy
- Laboratory parameters (see Table 8)
• Contraception
Post-treatment
• After discontinuation of infliximab, patients should be followed up with medical history and physical examination
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Therapeutic recommendations
Therapeutic combinations
Table 8 Recommended lab controls – inﬂiximab
Parameter Period in weeks
Pre-treatment 2 6 Thereafter, prior
to each infusion
Full blood count x x x x
Liver enzymes x x x x
Serum creatinine x x x x
Urine status x x x x
Pregnancy test (urine) x
CRP x
HBV/HCV x
HIV x
Not all tests may be necessary for all patients. Patient history, risk exposure and patient
characteristics have to be taken into account. Further speciﬁc testing may be required according to
clinical signs, risk and exposure.
Recommendation Strength of consensus Comment
We recommend inﬂiximab as second-line* medication for the induction and
long-term treatment.
↑↑ Strong consensus Evidence and consensus based
We recommend using inﬂiximab 5 mg/kg bodyweight continuously every
eight weeks during long-term treatment.
↑↑ Strong consensus Evidence and consensus based
*If phototherapy and conventional systemic agents were inadequate in response or if they are contraindicated or not tolerated.
Recommendation Strength of consensus Comments
Acitretin o Consensus No evidence available
Ciclosporin ↓ Consensus Expert opinion: increased risk of immunosuppression
Fumaric acid esters ↓ Consensus Expert opinion: increased risk of immunosuppression, lymphocytopenia
Methotrexate ↑ Consensus Expert opinion: combination widely used in rheumatology; combination with low-
dose MTX (e.g. 7.5–10 mg/week is likely sufﬁcient to reduce formation of ADA and
increase trough levels of inﬂiximab)
Ustekinumab ↓ Consensus Expert opinion: increased risk of immunosuppression
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Ustekinumab
Instructions for use
Pre-treatment
• Physicians are encouraged to enrol their patients in a registry (if available)
• Objective assessment of disease (such as PASI/BSA/PGA; arthritis)
• HRQoL (such as DLQI/Skindex-29 or -17)
• History and clinical examination focusing on previous treatment exposure, UV light, malignancies, infections
• Recommended measures include:
- Check for skin cancer
- Check for lymphadenopathy
- Laboratory parameters (see Table 9)
- Exclusion of tuberculosis (see chapter 5.1 in long version)
- Evaluation of comorbidities including cardiovascular risk factors
- Check for evidence of active infection
• Contraception
During treatment
• Objective assessment of disease (such as PASI/BSA/PGA; arthritis)
• Patient oriented outcomes such as pruritus, DLQI and Skindex-29 or -17
• History and clinical examination focusing on malignancies and infections
• Recommended measures include:
- Check for skin cancer and lymphadenopathy
- Pregnancy
- Evaluation of treatment adherence
Post-treatment
• Patients should be followed up with medical history and clinical examination
• Contraception to be maintained for 15 weeks
Table 9 Recommended lab controls – ustekinumab
Parameter Period in weeks/months
Pre-treatment Thereafter every 3–6 months
Full blood count x x
Liver enzymes x x
Serum creatinine x x
Urine status x x
Pregnancy test (urine) x
CRP x
HBV/HCV x
HIV x
Not all tests may be necessary for all patients. Patient history, risk exposure and patient
characteristics have to be taken into account. Further speciﬁc testing may be required
according to clinical signs, risk and exposure.
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Therapeutic recommendations
Therapeutic combinations
Special considerations and special patient populations
Tuberculosis (TB) screening before and during biologic treatment
Hepatitis/other hepatological dysfunctions
Recommendation Strength of consensus Comment
We recommend ustekinumab as second-line medication* for the induction and
long-term treatment.
↑↑ Strong consensus Evidence and consensus based
We suggest using 45 mg for patients with a bodyweight of ≤100 kg and 90 mg
ustekinumab for patients with a bodyweight of >100 kg.
↑ Strong consensus Evidence and consensus based
*if phototherapy and conventional systemic agents were inadequate in response or if they are contraindicated or not tolerated (the label currently states: if PUVA or other
systemic therapies including ciclosporin, methotrexate were inadequate in response or if they are contraindicated or not tolerated). No strong consensus on definition of
‘second-line’ for ustekinumab was achieved, the definition passed with ‘weak consensus’ (55%).
Recommendation Strength of consensus Comments
Acitretin o Consensus No evidence available
Adalimuab ↓ Consensus Expert opinion: increased risk of immunosuppression
Ciclosporin ↓ Consensus Expert opinion: increased immunosuppression, anecdotal
evidence of increased toxicity
Etanercept ↓ Consensus Expert opinion: increased risk of immunosuppression
Fumaric acid esters o Consensus No evidence available
Inﬂiximab ↓ Consensus Expert opinion: increased risk of immunosuppression
Methotrexate o Consensus No evidence available
Recommendation Strength of consensus Comment
We recommend to do tuberculosis screening according to local regulations. ↑↑ Strong consensus Expert opinion
For pre-screening, we recommend anamnesis including tuberculosis history;
a chest X-ray; TST and/or IGRA.
↑↑ Strong consensus Expert opinion
We recommend remaining alert to the possibility of tuberculosis infection
during therapy. This includes taking medical history and might include
tuberculosis testing.
↑↑ Strong consensus Expert opinion
Recommendation Strength of consensus Comment
We recommend to screen patients for hepatitis B and hepatitis C before starting treatment
with a biologic or methotrexate.
↑↑ Consensus Expert opinion
We recommend to screen patients for hepatitis B before starting treatment with ciclosporin. ↑↑ Consensus Expert opinion
If a positive marker is found, or the patient is known to have had prior infection we
recommend to consult a gastroenterologist with an interest in hepatology.
↑↑ Weak consensus Expert opinion
We recommend to record all cases of reactivation/ exacerbation via drug registries. ↑↑ Consensus Expert opinion
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HIV
Malignancies including lymphoma and skin cancer
Neurological disease
Recommendation Strength of consensus Comment
We recommend the combination of anti-retroviral therapy with topical therapies (steroids,
vitamin D derivatives, or combination of both) as ﬁrst-line treatment strategy for mild to
moderate psoriasis in HIV-infected patients.
↑↑ Strong consensus Expert opinion
For moderate-to-severe psoriasis, we recommend highly active anti-retroviral therapy with
skin-directed therapies, e.g. topicals and/or phototherapy (narrowband UVB mainly) as ﬁrst-
line strategy.
↑↑ Strong consensus Expert opinion
We suggest acitretin as second-line treatment in addition to highly active anti-retroviral
therapy.
↑ Strong consensus Expert opinion
We suggest using methotrexate or ciclopsorin or biologics only in patients with severe,
refactory psoriasis with well controlled HIV disease using HAART, in collaboration with a
specialist on HIV medicine.
↑ Strong consensus Expert opinion
In cases showing lack of response, intolerance, or contraindication to conventional systemic
immunosuppressants, we suggest to consider biologics.
↑ Consensus Expert opinion
We suggest using etanercept as biologic of choice in patients with severe, refactory
psoriasis with well controlled HIV disease using HAART.
↑ Consensus Expert opinion
Recommendation Strength of consensus Comment
For patients with recent malignancy we recommend topical therapies, phototherapy (narrow
band UVB) * and/or acitretin.
*except cutaneous malignancies
↑↑ Strong consensus Expert opinion
In case of inadequate response to topical therapies, phototherapy, (narrow band UVB) and/
or acitretin we suggest using MTX.
↑ Consensus Expert opinion
We recommend to discuss the decision to initiate immunosuppressive therapies, in
psoriasis patients with a current or recent diagnosis of cancer in the previous ﬁve years case
by case with cancer specialists and to reach an informed decision, respecting the patient’s
preference.
↑↑ Consensus Expert opinion
The elements to be taken into account for the shared decision are the type and staging of
cancer, the risk of recurrence and the burden of psoriasis in the individual patient.
Statement Strong consensus Expert opinion
In some cancers with relatively good prognosis, where ﬂares of psoriasis cannot be
controlled by other therapies, we suggest to consider earlier introduction of
immunosuppressive therapies. In this case, we suggest methotrexate as the preferred
systemic agent to be used.
↑ Strong consensus Expert opinion
In patients with concurrent cancer treatment who are treated with immunosuppressive
agents, we recommend to perform a search for pharmacological interactions in coordination
with the oncologist.
↑↑ Consensus Expert opinion
Recommendation Strength of consensus Comment
We do not recommend TNF antagonist therapy in people with diagnosis of multiple sclerosis
or other demyelinating disease.
↓↓ Strong consensus Expert opinion
We recommend caution using TNF antagonist therapy in people with a ﬁrst degree relative
with multiple sclerosis or other demyelinating disease.
↑↑ Strong consensus Expert opinion
We suggest choosing fumaric acid esters in people with multiple sclerosis. ↑ Strong consensus Expert opinion
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Ischaemic heart disease and congestive heart failure
Diabetes mellitus
Kidney failure/Renal impairment
Wish for pregnancy in near future
Recommendation Strength of consensus Comment
We recommend not using CSA as a ﬁrst-line treatment in patients with arterial hypertension. ↓↓ Strong consensus Expert opinion
We suggest not using TNF antagonists in subjects with NHHA class III or IV congestive
heart failure.
↓ Consensus Expert opinion
Recommendation Strength of consensus Comment
We suggest not using ciclosporin as a ﬁrst-line treatment in patients with diabetes and/or
features of the metabolic syndrome.
↓ Consensus Expert opinion
We suggest not using acitretin as a ﬁrst-line treatment in patients with dyslipidaemia. ↓ Consensus Expert opinion
Recommendation Strength of consensus Comment
We recommend ensuring an accurate assessment of renal function in any patient with
known or suspected chronic kidney disease prior to therapy.
↑↑ Strong consensus Expert opinion
We recommend working in collaboration with the nephrologist when prescribing systemic
therapy in any patient with chronic kidney disease of stage 3 or more.
↑↑ Strong consensus Expert opinion
We suggest using methotrexate, acitretin, or biological therapy in people with chronic kidney
disease stage 2–3.
↑ Consensus Expert opinion
We recommend using a reduced dose of methotrexate in people with chronic kidney disease
stage 3.
↑↑ Consensus Expert opinion
In people with chronic kidney disease stage 4–5 biologics can be used. Statement Strong consensus Expert opinion
We recommend not using ciclosporin or fumaric acid esters in chronic kidney disease stage
3 or more.
↓↓ Strong consensus Expert opinion
We recommend not using methotrexate in chronic kidney disease 4 or 5. ↓↓ Strong consensus Expert opinion
Recommendation Strength of consensus Comment
We recommend to advise the use of topical emollients, and low to moderate strength
corticosteroids of short duration as ﬁrst-line therapy in women with a wish for pregnancy in
the near future or who are pregnant.
↑↑ Consensus Expert opinion
We recommend phototherapy with narrow band UVB for women who are inadequately
controlled by emollients and topical steroids who wish to become pregnant or who are
pregnant.
↑↑ Strong consensus Expert opinion
For pregnant women with severe psoriasis requiring systemic therapy for which the beneﬁts
outweigh the risk, we suggest to consider etanercept.
↑ Strong consensus Expert opinion
We recommend not using acitretin and methotrexate in women considering becoming
pregnant or who are pregnant.
↓↓ Consensus Expert opinion
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Psoriatic arthritis
Newly approved medications and treatments in
the pipeline
The field of psoriasis treatments is evolving rapidly and several
new treatments have been developed. For any guideline, it is a
challenge to be up to date with the rapidly changing market of
psoriasis treatments. New medications with very little use during
regular clinical practice are difficult to assess with expert opinion
knowledge. The guideline group has decided to focus on the
licensed treatment options at the time point of the consensus
conference. The group decided against a prospective inclusion of
new drugs that are likely to be licensed in the near future, espe-
cially also in the light of lack of expert experience with these
new drugs.
Since the cut off date for inclusion of approved medications
in Europe (October 2014), secukinumab and apremilast have
been granted market authorization by EMA.6,7 An update
including newly approved medications is currently under prepa-
ration.
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Supporting information
Additional Supporting Information may be found in the online
version of this article:
Data S1. Long version: European S3-Guidelines on the systemic
treatment of psoriasis vulgaris – update 2015 – EDF in coop-
eration with EADV and IPC.
Recommendation Strength of consensus Comment
For relief of symptoms of psoriatic arthritis, we recommend NSAIDs. As a monotherapy, we
recommend NSAIDs for patients with mild and non-erosive articular as well as para-articular
involvement.
↑↑ Strong consensus Expert opinion
In patients with active joint involvement despite the usage of NSAIDs and potential poor
prognosis due to polyarthritis, increased inﬂammatory markers and erosive changes, we
recommend to start synthetic DMARDs early to prevent progression of disease and erosive
destruction of joints.
↑↑ Consensus Expert opinion
For inadequately responding patients after at least one synthetic DMARD, we recommend
the use of biological DMARDs in combination with synthetic DMARDs or as monotherapy.
↑↑ Consensus Expert opinion
We do not recommend synthetic monotherapy DMARDs for the treatment of axial
involvement or enthesitis, as they appear to be not effective in these patients.
↓↓ Strong consensus Expert opinion
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